BNP Paribas Financial Markets Buys Shares of 122,373 Genmab A/S (NASDAQ:GMAB)

BNP Paribas Financial Markets purchased a new stake in shares of Genmab A/S (NASDAQ:GMAB - Free Report) in the fourth quarter, according to its most recent 13F filing with the SEC. The fund purchased 122,373 shares of the company's stock, valued at approximately $2,554,000.

Several other institutional investors have also recently made changes to their positions in the company. Renaissance Technologies LLC boosted its stake in Genmab A/S by 7.8% during the fourth quarter. Renaissance Technologies LLC now owns 1,926,150 shares of the company's stock valued at $40,199,000 after buying an additional 139,722 shares during the period. First Trust Advisors LP grew its holdings in shares of Genmab A/S by 18.0% during the fourth quarter. First Trust Advisors LP now owns 1,644,288 shares of the company's stock worth $34,316,000 after purchasing an additional 251,241 shares in the last quarter. Brandywine Global Investment Management LLC purchased a new position in shares of Genmab A/S during the fourth quarter worth about $33,804,000. Marshall Wace LLP increased its holdings in shares of Genmab A/S by 162.2% in the 4th quarter. Marshall Wace LLP now owns 1,122,296 shares of the company's stock worth $23,422,000 after buying an additional 694,243 shares during the last quarter. Finally, Northern Trust Corp boosted its holdings in shares of Genmab A/S by 18.8% in the 4th quarter. Northern Trust Corp now owns 599,381 shares of the company's stock worth $12,509,000 after purchasing an additional 94,858 shares in the last quarter. Institutional investors own 7.07% of the company's stock.

Genmab A/S Stock Up 0.7%

Genmab A/S stock traded up $0.15 during trading hours on Tuesday, hitting $20.33. The stock had a trading volume of 1,029,673 shares, compared to its average volume of 1,111,499. The stock's 50-day moving average price is $19.74 and its 200-day moving average price is $20.73. The stock has a market capitalization of $13.04 billion, a P/E ratio of 11.68, a price-to-earnings-growth ratio of 2.65 and a beta of 1.04. Genmab A/S has a 12-month low of $17.24 and a 12-month high of $30.06.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported $0.31 earnings per share for the quarter, topping analysts' consensus estimates of $0.23 by $0.08. The company had revenue of $715.00 million during the quarter, compared to analyst estimates of $5.17 billion. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. On average, research analysts expect that Genmab A/S will post 1.45 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have recently weighed in on GMAB. HC Wainwright reissued a "buy" rating and issued a $37.00 target price (down previously from $50.00) on shares of Genmab A/S in a research note on Wednesday, April 9th. Truist Financial lowered their price objective on shares of Genmab A/S from $50.00 to $45.00 and set a "buy" rating for the company in a report on Tuesday, March 11th. Leerink Partnrs raised shares of Genmab A/S from a "hold" rating to a "strong-buy" rating in a research report on Thursday, February 13th. William Blair raised shares of Genmab A/S from a "market perform" rating to an "outperform" rating in a research report on Tuesday, March 11th. Finally, Leerink Partners raised shares of Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 price objective on the stock in a research note on Thursday, February 13th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $39.17.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.